490 related articles for article (PubMed ID: 16234514)
1. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group.
Knoop AS; Knudsen H; Balslev E; Rasmussen BB; Overgaard J; Nielsen KV; Schonau A; Gunnarsdóttir K; Olsen KE; Mouridsen H; Ejlertsen B;
J Clin Oncol; 2005 Oct; 23(30):7483-90. PubMed ID: 16234514
[TBL] [Abstract][Full Text] [Related]
2. The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
Nielsen KV; Ejlertsen B; Møller S; Jørgensen JT; Knoop A; Knudsen H; Mouridsen HT
Acta Oncol; 2008; 47(4):725-34. PubMed ID: 18465341
[TBL] [Abstract][Full Text] [Related]
3. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil.
Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ
Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526
[TBL] [Abstract][Full Text] [Related]
4. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401.
; Tanner M; Isola J; Wiklund T; Erikstein B; Kellokumpu-Lehtinen P; Malmström P; Wilking N; Nilsson J; Bergh J
J Clin Oncol; 2006 Jun; 24(16):2428-36. PubMed ID: 16682728
[TBL] [Abstract][Full Text] [Related]
5. HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients.
Ejlertsen B; Jensen MB; Nielsen KV; Balslev E; Rasmussen BB; Willemoe GL; Hertel PB; Knoop AS; Mouridsen HT; Brünner N
J Clin Oncol; 2010 Feb; 28(6):984-90. PubMed ID: 20038724
[TBL] [Abstract][Full Text] [Related]
6. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial.
Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ
J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial.
O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI
Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837
[TBL] [Abstract][Full Text] [Related]
8. TIMP-1 in combination with HER2 and TOP2A for prediction of benefit from adjuvant anthracyclines in high-risk breast cancer patients.
Hertel PB; Tu D; Ejlertsen B; Jensen MB; Balslev E; Jiang S; O'Malley FP; Pritchard KI; Shepherd LE; Bartels A; Brünner N; Nielsen TO
Breast Cancer Res Treat; 2012 Feb; 132(1):225-34. PubMed ID: 22160637
[TBL] [Abstract][Full Text] [Related]
9. Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Pierceall WE; Sprott KM; Heikkinen T; Heikkila P; Alaparthi L; Aittomaki K; Al-Adhami M; Villegas-Bergazzi V; Meyer JL; Kutok JL; Bartkova J; Bartek J; Nevanlinna H; Weaver DT; Blomqvist C
Hum Pathol; 2012 Sep; 43(9):1363-75. PubMed ID: 22204715
[TBL] [Abstract][Full Text] [Related]
10. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
[TBL] [Abstract][Full Text] [Related]
11. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.
Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M;
Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518
[TBL] [Abstract][Full Text] [Related]
12. TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer.
Villman K; Sjöström J; Heikkilä R; Hultborn R; Malmström P; Bengtsson NO; Söderberg M; Saksela E; Blomqvist C
Acta Oncol; 2006; 45(5):590-6. PubMed ID: 16864174
[TBL] [Abstract][Full Text] [Related]
13. HER2 and responsiveness of breast cancer to adjuvant chemotherapy.
Pritchard KI; Shepherd LE; O'Malley FP; Andrulis IL; Tu D; Bramwell VH; Levine MN;
N Engl J Med; 2006 May; 354(20):2103-11. PubMed ID: 16707747
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5.
Levine MN; Pritchard KI; Bramwell VH; Shepherd LE; Tu D; Paul N;
J Clin Oncol; 2005 Aug; 23(22):5166-70. PubMed ID: 16051958
[TBL] [Abstract][Full Text] [Related]
15. Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study.
Willemoe GL; Hertel PB; Bartels A; Jensen MB; Balslev E; Rasmussen BB; Mouridsen H; Ejlertsen B; Brünner N
Eur J Cancer; 2009 Sep; 45(14):2528-36. PubMed ID: 19535243
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer.
Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496
[TBL] [Abstract][Full Text] [Related]
17. TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
Wang J; Xu B; Yuan P; Zhang P; Li Q; Ma F; Fan Y
Breast Cancer Res Treat; 2012 Sep; 135(2):531-7. PubMed ID: 22864769
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
19. HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients.
Zhu L; Li YF; Chen WG; He JR; Peng CH; Zhu ZG; Li HW
Chin Med J (Engl); 2008 Oct; 121(20):1965-8. PubMed ID: 19080257
[TBL] [Abstract][Full Text] [Related]
20. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer.
Andre F; Mazouni C; Liedtke C; Kau SW; Frye D; Green M; Gonzalez-Angulo AM; Symmans WF; Hortobagyi GN; Pusztai L
Breast Cancer Res Treat; 2008 Mar; 108(2):183-90. PubMed ID: 17468948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
